Published in JAMA on September 24, 1982
Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol (2005) 5.30
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Multiple behavior changes in diet and activity: a randomized controlled trial using mobile technology. Arch Intern Med (2012) 3.35
Research into complementary and alternative medicine: problems and potential. BMJ (2001) 2.97
Could targeted food taxes improve health? J Epidemiol Community Health (2007) 2.66
Number needed to screen: development of a statistic for disease screening. BMJ (1998) 2.56
Isoprenoids as mediators of the biological effects of statins. J Clin Invest (2002) 2.19
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag (2005) 2.15
A multilocus genotyping assay for candidate markers of cardiovascular disease risk. Genome Res (1999) 2.13
Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev (2006) 2.04
A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J (2007) 2.01
A multidimensional integrative medicine intervention to improve cardiovascular risk. J Gen Intern Med (2006) 1.73
Epidemiology and genetics of sudden cardiac death. Circulation (2012) 1.65
Comorbidities of diabetes and hypertension: mechanisms and approach to target organ protection. J Clin Hypertens (Greenwich) (2011) 1.59
Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol (2005) 1.55
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
Partnerships for the design, conduct, and analysis of effectiveness, and implementation research: experiences of the prevention science and methodology group. Adm Policy Ment Health (2012) 1.47
Long-term effects of chlorthalidone versus hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the multiple risk factor intervention trial. Hypertension (2011) 1.46
A randomized controlled trial of stress reduction in African Americans treated for hypertension for over one year. Am J Hypertens (2005) 1.45
On paradigms, community participation, and the future of public health. Am J Public Health (1997) 1.36
Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with metabolic syndrome. Atherosclerosis (2006) 1.35
The spectrum of epidemiology underlying sudden cardiac death. Circ Res (2015) 1.26
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci (2011) 1.12
Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry (Edgmont) (2009) 1.10
A randomized controlled trial on effects of the Transcendental Meditation program on blood pressure, psychological distress, and coping in young adults. Am J Hypertens (2009) 1.05
Genetic association of glutathione peroxidase-1 with coronary artery calcification in type 2 diabetes: a case control study with multi-slice computed tomography. Cardiovasc Diabetol (2007) 1.03
Effects of the Heartbeat Wales programme. Effects of government policies on health behaviour must be studied. BMJ (1998) 1.01
Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care (2013) 0.98
The Multifactor Primary Prevention Trial in Göteborg, Sweden. Comparison with a previously untreated population sample. Drugs (1986) 0.97
High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. Vasc Health Risk Manag (2008) 0.97
Serum lipoproteins during treatment with antihypertensive drugs. Drugs (1988) 0.97
Relation of heart rate parameters during exercise test to sudden death and all-cause mortality in asymptomatic men. Am J Cardiol (2008) 0.96
Atorvastatin induces apoptosis by a caspase-9-dependent pathway: an in vitro study on activated rat hepatic stellate cells. Liver Int (2008) 0.96
Phase II clinical research design in cardiology: learning the right lessons too well: observations and recommendations from the Cardiovascular Cell Therapy Research Network (CCTRN). Circulation (2013) 0.95
Drug Insight: statins and stroke. Nat Clin Pract Cardiovasc Med (2005) 0.94
The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) (2010) 0.93
The cholesterol-heart disease hypothesis (critique)--time to change course? Bull N Y Acad Med (1989) 0.92
Primary prevention of cardiovascular disease using validated risk scores: a systematic review. J R Soc Med (2012) 0.92
The covariation of multiple risk factors in primary care: a latent class analysis. J Behav Med (2008) 0.92
The effect of quitting smoking on HDL-cholesterol - a review based on within-subject changes. Biomark Res (2013) 0.91
Inclusion of women in clinical trials. BMC Med (2009) 0.91
Eosinophil count is positively correlated with albumin excretion rate in men with type 2 diabetes. Clin J Am Soc Nephrol (2009) 0.89
Diuretics and arrhythmias in the Medical Research Council trial. Drugs (1984) 0.89
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Expert Rev Cardiovasc Ther (2009) 0.88
Change for Life/Cambia tu vida: A health promotion program based on the stages of change model for African descendent and Latino adults in New Hampshire. Prev Chronic Dis (2006) 0.88
DAMASCENE and Meta-Ecological Research: A Bridge Too Far. Circ Res (2014) 0.87
Coronary imaging quality in routine ECG-gated multidetector CT examinations of the entire thorax: preliminary experience with a 64-slice CT system in 133 patients. Eur Radiol (2006) 0.87
Letter by Kuller and Neaton Regarding Article, "Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans". Circulation (2016) 0.86
Timeline of History of Hypertension Treatment. Front Cardiovasc Med (2016) 0.86
Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels (2011) 0.86
Patient education: a public health point of view. Bull N Y Acad Med (1985) 0.86
Hypertension in Cardiovascular and Kidney Disease. Cardiorenal Med (2011) 0.85
Census-based and personally reported income measures as long-term risk-adjusted mortality predictors. Public Health (2007) 0.84
The drug treatment of mild hypertension in the Multiple Risk Factor Intervention Trial. A review. Drugs (1986) 0.84
Diuretic drugs. Progress in clinical pharmacology. Drugs (1986) 0.84
Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J Am Heart Assoc (2012) 0.83
Generalizability of guidelines and physicians' adherence. Case study on the Sixth Joint National Commitee's guidelines on hypertension. BMC Public Health (2003) 0.83
Racial differences in antihypertensive therapy: evidence and implications. Cardiovasc Drugs Ther (1990) 0.83
An Evaluation of the Clinical Evidence on the Role of Inflammation and Oxidative Stress in Smoking-Mediated Cardiovascular Disease. Biomark Insights (2008) 0.83
Electrolyte abnormalities and ventricular arrhythmias. Drugs (1986) 0.82
Reducing risk behaviors linked to noncommunicable diseases in Mongolia: a randomized controlled trial. Am J Public Health (2013) 0.81
Regression of left ventricular hypertrophy; what are appropriate therapeutic objectives? Br J Clin Pharmacol (1999) 0.81
The efficacy of beta-adrenoceptor and calcium-entry blockers in hypertensive blacks. Cardiovasc Drugs Ther (1990) 0.81
N-terminal pro-brain natriuretic peptide could be a marker of subclinical atherosclerosis in patients with type 2 diabetes. Heart Vessels (2012) 0.81
Interrelationship of hypertension, plasma lipids and atherosclerosis. Drugs (1988) 0.80
Women's health and clinical trials. J Clin Invest (2003) 0.80
The independent impact of congestive heart failure status and diuretic use on serum uric acid among men with a high cardiovascular risk profile: a prospective longitudinal study. Semin Arthritis Rheum (2011) 0.80
Treatment of specific macrovascular beds in patients with diabetes mellitus. Osteopath Med Prim Care (2010) 0.79
Effects of treatment with verapamil SR and captopril on the lipid profile of hypertensive patients. Drugs (1992) 0.78
Sex and the Lab: An Alcohol-Focused Commentary on the NIH Initiative to Balance Sex in Cell and Animal Studies. Alcohol Clin Exp Res (2016) 0.78
Are concomitant treatments confounding factors in randomized controlled trials on intensive blood-glucose control in type 2 diabetes? a systematic review. BMC Med Res Methodol (2013) 0.78
Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazide diuretic reduces coronary mortality and sudden cardiac death. J Am Soc Hypertens (2010) 0.78
Prevalence of Self-reported Cardiovascular Risk Factors among Saudi Physicians: A Comparative Study. Int J Health Sci (Qassim) (2013) 0.77
Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination. Integr Blood Press Control (2011) 0.77
Response to Letter Regarding Article, "Association of Race With Mortality and Cardiovascular Events in a Large Cohort of US Veterans". Circulation (2016) 0.77
A cross-sectional study of the prevalence and correlates of tobacco use in Chennai, Delhi, and Karachi: data from the CARRS study. BMC Public Health (2015) 0.77
Physical Activity and Lipid Profile in the ELSA- Brasil Study. Arq Bras Cardiol (2016) 0.77
The role of academic medicine in patient education. In pursuit of hypertension program problems. Bull N Y Acad Med (1985) 0.77
Statistical Methods for Cardiovascular Researchers. Circ Res (2016) 0.76
Efficacy and safety of carvedilol in comparison with atenolol in hypertensive patients pretreated with hydrochlorothiazide. Eur J Clin Pharmacol (1990) 0.76
Role of the angiotensin II receptor blocker valsartan in heart failure. Exp Clin Cardiol (2001) 0.76
The diuretic dilemma and the management of mild hypertension. Drugs (1986) 0.76
Does Renal Artery Stenting Prevent Clinical Events? Clin J Am Soc Nephrol (2016) 0.76
Benefit-Risk Assessment of Fish Oil in Preventing Cardiovascular Disease. Drug Saf (2016) 0.75
Effect Sizes and Primary Outcomes in Large-Budget, Cardiovascular-Related Behavioral Randomized Controlled Trials Funded by NIH Since 1980. Ann Behav Med (2016) 0.75
Long-term therapy of hypertension. Korean J Intern Med (1995) 0.75
Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor? Curr Cardiol Rev (2008) 0.75
Experiences from hypertension trials--effects on stroke and coronary heart disease. Drugs (1988) 0.75
Interpreting angina: symptoms along a gender continuum. Open Heart (2016) 0.75
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. Vasc Health Risk Manag (2007) 0.75
Patient education in historical perspective. Bull N Y Acad Med (1985) 0.75
Lipid profile studies in long term thiazide treated hypertensives. Postgrad Med J (1991) 0.75
Progression from metabolically benign to at-risk obesity in perimenopausal women: a longitudinal analysis of study of women across the nation (SWAN). J Clin Endocrinol Metab (2014) 0.75
Impact of a traditional dietary supplement with coconut milk and soya milk on the lipid profile in normal free living subjects. J Nutr Metab (2013) 0.75
What can we do about exploratory analyses in clinical trials? Contemp Clin Trials (2015) 0.75
Ventricular arrhythmias in patients with myocardial infarction and ischaemia. The role of serum potassium. Drugs (1986) 0.75
The Obesity Paradox in Recurrent Attacks of Gout in Observational Studies: Clarification and Remedy. Arthritis Care Res (Hoboken) (2016) 0.75
Women in clinical research: what we need for progress. Circ Cardiovasc Qual Outcomes (2015) 0.75
Ernst Wynder: a remembrance. Prev Med (2006) 0.75